% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
administrative expenses for the three months period ended 31 March 2018 and 2019 at THB 34.11 million and THB 40.14 million respectively. This equals to a surge of 17.68 % in administrative expenses year on year
& expenses (net of tax) from the comparing quarters, the normalized net profit would be approximately THB 72.8 million in 2Q19 comparing to THB 52.4 million in 2Q18 or a surge of 39% . Statement of Financial
. Tambon Tarsit, Amohoe Pluag-daeng, Rayong As of June 30, 2018 the Company and its subsidiary had a significant surge in trade and other receivables when compared to last year which was mainly from an
YoY. Transfer ownership of condominium unit of the ESSE at Singha Complex, the ESSE Asoke and Banyan Tree Residences Riverside Bangkok mainly attributed to the surge. Residential projects for sales as
% YoY. Transfer ownership of condominium unit of the ESSE at Singha Complex since September 2019, the ESSE Asoke and Banyan Tree Residences Riverside Bangkok mainly attributed to the surge. Residential
, inventories and property, plant and equipment. Cash received from the initial public offering (IPO) and cash from operations contributed to the surge in total assets. Total Liabilities As of 30 June 2018, the
shareholders’ equity of THB 4,973.36 million. The surge in shareholders’ equity was mainly caused by the Company’s initial public offering (IPO) as well as the retained earnings from the Company’s performance